COMMUNIQUÉS West-GlobeNewswire

GlycoPezil Supplement Claims Evaluated - Complete Investigation of the Blood Sugar Support Ingredients
12/03/2026
A 2026 consumer research report examining GlycoPezil's ingredient research references, proprietary blend structure, pricing transparency, and verification considerations for adults researching blood sugar support [...]
Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
12/03/2026
NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS, NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving [...]
Cellectis publiera ses résultats financiers du quatrième trimestre et de l’année 2025 le 19 mars 2026
12/03/2026
NEW YORK, 12 mars 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa technologie pionnière d’édition du génome TALEN® pour développer [...]
Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
12/03/2026
– Announced FDA acceptance of NDA for lorundrostat in adults with hypertension; assigned PDUFA target date of December 22, 2026 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., March 12, 2026 (GLOBE NEWSWIRE [...]
Surgery Partners, Inc. Names Lloyd Dean to Board of Directors
12/03/2026
BRENTWOOD, Tenn., March 12, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”) recently announced that Lloyd Dean has been appointed to serve as an independent director [...]
OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
12/03/2026
-- Data from the ongoing PIKture-01 trial is expected to be announced in March 2026 ; continued enrollment in breast cancer triplet combinations -- Next-generation PI3K α pan-mutant inhibitor development candidate for [...]
IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026
12/03/2026
Presented updated glioblastoma (“GBM”) data demonstrating durable survival and a favorable safety profile across Phase 1 and Phase 2 programs, with repeat dosing of DeltEx™ Drug-Resistant Immunotherapy γδ T cells (“DRI [...]
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
12/03/2026
First-in-class immune-stimulating antibody conjugate BDC-4182 in Phase 1 dose escalation study, initial clinical data expected in 3Q 2026 Cash balance of $31.8 million as of December 31, 2025 anticipated to fund key [...]
BioSyent Schedules Fourth Quarter and Full Year 2025 Earnings Release for March 19, 2026
12/03/2026
MISSISSAUGA, Ontario, March 12, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the fourth quarter and full year ended December 31, 2025 on [...]
Voting Rights and Shares Capital of the Company
12/03/2026
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, March 12, 2026 (GLOBE NEWSWIRE [...]
Health Catalyst Reports Fourth Quarter and Year End 2025 Results
12/03/2026
SALT LAKE CITY, March 12, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported [...]
Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
12/03/2026
Event-driven primary disease-free survival (“DFS”) analysis for Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (“PDAC”) is anticipated in 1H 2026 Fewer disease [...]
Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
12/03/2026
Nominated KRRO-121 development candidate for the potential treatment of hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy Advanced GalNAc-conjugated oligonucleotide for alpha-1 antitrypsin [...]
Aeroflow Health Earns 2026 Great Place To Work Certification™
12/03/2026
ASHEVILLE, N.C., March 12, 2026 (GLOBE NEWSWIRE) -- Aeroflow Health is proud to be Certified™ by Great Place To Work®. The prestigious award is based entirely on what current employees say about their experience working [...]
Koelis annonce, à l’occasion du Congrès de l’EAU 2026, des innovations technologiques destinées à optimiser les flux de travail de biopsie par fusion IRM et à soutenir le développement de la thérapie focale dans la prise en charge du cancer de la prostate
12/03/2026
GRENOBLE, France, 12 mars 2026 (GLOBE NEWSWIRE) -- Koelis, SAS (« Koelis » ou la « Société », www.koelis.com ), leader technologique et acteur innovant dans le domaine du guidage par fusion IRM-échographie appliqué aux [...]
SK pharmteco annonce la certification CGMP de son site de production de vecteurs viraux à échelle commerciale en France
12/03/2026
RANCHO CORDOVA, Californie, 12 mars 2026 (GLOBE NEWSWIRE) -- SK pharmteco a annoncé aujourd'hui le succès de la certification CGMP de son usine de fabrication à Corbeil-Essonnes, en France. Cette usine de pointe est [...]
Sanofi: Information concerning the total number of voting rights and shares - February 2026
12/03/2026
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’ [...]
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
12/03/2026
COPENHAGEN, Denmark, March 12, 2026 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company’s shares/related securities by persons holding managerial [...]
Sanofi: Informations relatives au nombre de droits de vote et d'actions - FEVRIER 2026
12/03/2026
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers Sanofi Société [...]

Pages